Research PaperSelective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin (cas 19683-98-8) in endothelial cells
-
Add time:09/09/2019 Source:sciencedirect.com
Background: The angiogenesis inhibitors TNP-470 and ovalicin (cas 19683-98-8) potently suppress endothelial cell growth. Both drugs also specifically inhibit methionine aminopeptidase 2 (MetAP2) in vitro. Inhibition of MetAP2 and changes in initiator methionine removal in drug-treated endothelial cells have not been demonstrated, however.Results: Concentrations of TNP-470 sufficient to inactivate MetAP2 in intact endothelial cells were comparable to those that inhibited cell proliferation, suggesting that MetAP2 inhibition by TNP-470 underlies the ability of the drug to inhibit cell growth. Both drug-sensitive and drug-insensitive cell lines express MetAP1 and MetAP2, indicating that drug sensitivity in mammalian cells is not simply due to the absence of compensating MetAP activity. With a single exception, detectable protein N-myristoylation is unaffected in sensitive endothelial cells treated with TNP-470, so MetAP1 activity can generally compensate when MetAP2 is inactive. Analysis of total protein extracts from cells pulse-labeled with [35S]-methionine following TNP-470 treatment revealed changes in the migration of several newly synthesized proteins. Two of these proteins were identified as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cyclophilin A. Purification and amino-terminal sequencing of GAPDH from TNP-470-treated cells revealed partial retention of its initiator methionine, indicating that methionine removal from some, but not all, proteins is affected by MetAP2 inactivation.Conclusions: Amino-terminal processing defects occur in cells treated with TNP-470, indicating that inhibition of MetAP2 by the drug occurs in intact cells. This work renders plausible a mechanism for growth inhibition by TNP-470 as a consequence of initiator methionine retention, leading to the inactivation of as yet unidentified proteins essential for endothelial cell growth.
We also recommend Trading Suppliers and Manufacturers of ovalicin (cas 19683-98-8). Pls Click Website Link as below: cas 19683-98-8 suppliers
Prev:Enantioselective formal synthesis of (−)-ovalicin (cas 19683-98-8) using quinic acid as a chiral template1
Next:Preparation of 1,6-di-deoxy-d-galacto and 1,6-di-deoxy-l-altro nojirimycin derivatives by aminocyclization of a 1,5-dicarbonyl derivative) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Enantioselective formal synthesis of (−)-ovalicin (cas 19683-98-8) using quinic acid as a chiral template109/08/2019
- The biosynthesis of ovalicin (cas 19683-98-8) from β-trans-bergamotene09/07/2019
- QSAR of the inhibition of angiogenesis by TNP-470 and ovalicin (cas 19683-98-8) analogues: another example of an allosteric interaction09/06/2019
- Synthetic analogues of TNP-470 and ovalicin (cas 19683-98-8) reveal a common molecular basis for inhibition of angiogenesis and immunosuppression109/05/2019
- Simple and efficient synthesis of highly functionalized cyclohexanes; formal total synthesis of ovalicin (cas 19683-98-8) and fumagillin09/04/2019
- A novel stereoselective route to a fumagillin and ovalicin (cas 19683-98-8) synthetic intermediate09/03/2019
- The allenic Alder-ene reaction: constitutional group selectivity and its application to the synthesis of ovalicin (cas 19683-98-8)09/02/2019
- Research paperMethionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin (cas 19683-98-8)09/01/2019
- Total syntheses of (±)-ovalicin (cas 19683-98-8), C4(S∗)-isomer, and its C5-analogs and anti-trypanosomal activities08/31/2019


